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OBJECTIVES The goal of this work was to study the effects of short-term infusion of dobutamine on
efferent cardiac sympathetic activity.
BACKGROUND Increased efferent cardiac sympathetic activity is associated with poor outcomes in the setting
of congestive heart failure (CHF). Dobutamine is commonly used in the therapy of
decompensated CHF. Dobutamine, through its effects on excitatory beta-receptors, may
increase cardiac sympathetic activity.
METHODS Seven patients with normal left ventricular (LV) function and 13 patients with CHF were
studied. A radiotracer technique was used to measure cardiac norepinephrine spillover
(CANESP) before and during an intravenous infusion of dobutamine titrated to increase the
rate of rise in LV peak positive pressure (dP/dt) by 40%.
RESULTS Systemic arterial pulse pressure increased significantly in response to dobutamine in the
normal LV function group (74  3 mm Hg to 85  3 mm Hg, p  0.005) but remained
unchanged in the CHF group. Dobutamine caused a significant decrease in LV end-diastolic
pressure in the CHF group (14  2 mm Hg to 11  2 mm Hg, p  0.02), an effect not
observed in the normal LV group. In the normal LV function group, CANESP did not
change in response to dobutamine (75  22 pmol/min vs. 72  22 pmol/min, p  NS). In
contrast, dobutamine infusion was associated with a significant reduction in CANESP in
patients with CHF (199  43 pmol/min to 128  30 pmol/min, p  0.0009).
CONCLUSIONS Dobutamine infusion caused a significant sympatholytic response in patients with CHF. This
sympathetic withdrawal response is probably related to reduction of LV filling pressures
and/or activation of ventricular mechanoreceptors with dobutamine infusion. (J Am Coll
Cardiol 2002;39:1269–74) © 2002 by the American College of Cardiology Foundation
The detrimental effect of long-term oral positive inotropic
therapy in patients with advanced congestive heart failure
(CHF) is well established (1–3). Different classes of inotro-
pic agents including beta-adrenergic receptor agonists and
phosphodiesterase inhibitors have been evaluated in clinical
trials with neutral or negative effects (1–6). Despite the
failure of oral positive inotropic agents, intravenous positive
inotropic therapy continues to be used extensively in the
treatment of decompensated CHF. Dobutamine, a rela-
tively selective beta1-agonist, is one agent in widespread
clinical use for this indication (7,8). It is also used in
intermittent therapeutic regimens, although its efficacy and
safety in this setting remain controversial (9). Multiple
case-control studies and case series suggested that this
approach improved functional capacity and reduced hospital
admissions (10–13). However, a single randomized trial,
presented only in abstract form, described an increase in
mortality (14).
An important potential mechanism for adverse effects of
beta-agonist therapy in patients with CHF is via sympa-
thetic activation. Beta-agonists directly stimulate adrenergic
receptors on cardiac myocytes with possible adverse conse-
quences including increased arrhythmias and myocardial
ischemia (15). Beta-agonist therapy may also increase en-
dogenous norepinephrine release through stimulation of
facilitative prejunctional beta-receptors at several sites
within the sympathetic nervous system (16,17). We have
previously demonstrated that a beta2-agonist increases car-
diac sympathetic activity, presumably through an excitatory
prejunctional mechanism (18).
The purpose of the current study was to explore the
effects of acute beta-agonist administration on cardiac sym-
pathetic activity. We hypothesized that dobutamine would
cause an augmentation in cardiac sympathetic activity
through activation of sympathoexcitatory beta-adrenergic
receptors. To test this hypothesis we measured cardiac
norepinephrine spillover (CANESP) responses during the
acute administration of dobutamine in patients with CHF
and normal left ventricular (LV) function.
METHODS
Patients. The study population consisted of 20 patients.
Seven subjects with normal LV function (LV ejection
fraction: 56  2%, mean age: 62  3 years) underwent
coronary angiography to investigate a chest pain syndrome.
Four of these had coronary artery disease. In this group, six
of the patients received beta-blockers which included ateno-
lol (n  3, daily dose 50 mg), metoprolol (n  1, daily dose
100 mg), nadolol (n 1, daily dose 40 mg) and propranolol
(n  1, daily dose 80 mg), and one patient received an
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angiotensin receptor blocker. Thirteen patients had CHF
(LV ejection fraction: 21  3%, mean age: 62  2 years).
The etiology of the heart failure was ischemic in nine
patients and idiopathic in four patients. The medical ther-
apy consisted of metoprolol (n  4, mean dose 81 mg),
atenolol (n  1, daily dose 50 mg), carvedilol (n  1, daily
dose 25 mg), digoxin (n  7) and angiotensin-converting
enzyme inhibitor or angiotensin receptor antagonist (n 
11). The patients were on a stable dose of beta-blockers for
a minimum of eight weeks before participation in the study.
Eight patients had New York Heart Association functional
class II symptoms; four had functional class III symptoms
and one patient had functional class IV symptoms.
All medications were held on the morning of the study.
The University of Toronto Ethical Review Committee for
experimentation involving human subjects approved the
protocol. Written informed consent was obtained from all
participants.
Hemodynamic and coronary flow measurements. A di-
agnostic left and right heart catheterization from the fem-
oral approach was performed without sedation. After the
diagnostic procedure, the pulmonary artery catheter was left
in place. A 7F coronary sinus thermodilution catheter (type
CCS-7U-90B, Webster Laboratories, Baldwin Park, Cali-
fornia) was inserted from an antecubital vein and positioned
under fluoroscopic guidance in the coronary sinus for flow
measurements and blood sampling. A 7F micromanometer
tipped catheter (Millar Industries, Houston, Texas) was
placed in the LV. Femoral artery pressure was monitored via
an 8F side-arm sheath (Terumo Medical Corp., Elkton,
Maryland). Cardiac output was measured by the Fick
method. The electrocardiogram (ECG), right atrial pres-
sure, pulmonary artery pressure, femoral artery pressure, LV
pressure and its first derivative ([dP/dt] continuous elec-
tronic differentiation) were recorded on a strip chart re-
corder. For each variable, the results were expressed as an
average measurement of 10 cardiac cycles in patients with
sinus rhythm and 15 cardiac cycles in patients with atrial
fibrillation. Left ventricular pressure and the ECG were
digitally recorded at 300 Hz with a Macintosh personal
computer equipped with a multichannel analog-to-digital
converter. Data files were stored to disk for later analysis.
Left ventricular peak dP/dt values were calculated off-line
with customized software developed in Labview (Version
3.0, National Instruments Corp., Austin, Texas). Coronary
sinus blood flow measurements were performed in duplicate
at each measurement point according the method of Ganz
et al. (19).
Norepinephrine spillover measurements. Sympathetic
activity was estimated by the measurement of CANESP and
total body norepinephrine spillover (20). For these measure-
ments, tritiated norepinephrine (1 to 1.2 Ci/min with a
16 Ci priming bolus of L-[2,5,6-3H] norepinephrine;
New England Nuclear, Boston, Massachusetts) was infused
into a peripheral vein to steady-state concentration in
plasma. Norepinephrine clearance and spillover rates were
calculated as previously described (21,22).
Analysis of plasma catecholamines. Plasma catechol-
amine concentrations were measured by high-performance
liquid chromatography (HPLC) with electrochemical de-
tection. Fractions from the HPLC effluent containing
tritium-labeled norepinephrine were assayed by liquid scin-
tillation spectroscopy. These analyses were performed by
established methods in our laboratory by personnel blinded
to patient status (21,22).
Study protocol. After the diagnostic heart catheterization
and insertion of catheters for hemodynamic monitoring,
the patient was left undisturbed for a minimum of 20 min
for tritium-labeled norepinephrine to reach steady-state.
Baseline hemodynamic and coronary blood flow measure-
ments were obtained along with measures of CANESP
and total body norepinephrine spillover. Subsequently, an
intravenous infusion of dobutamine was initiated starting
at 2.5 g·kg1·min1. The dobutamine infusion rate was
increased until LV dP/dt had increased by 40%. Hemo-
dynamic, coronary sinus blood flow, CANESP and total
body norepinephrine spillover were reassessed 20 min after
this increase in LV dP/dt had been achieved. The dobut-
amine infusion was then discontinued, and recovery mea-
surements were performed once LVdP/dt had returned to
baseline values.
Statistical analysis. Data are presented as the mean value
 SEM. The analysis was performed using SAS (release
8.1, SAS Institute Inc., Cary, North Carolina). Between-
group comparisons of baseline characteristics were per-
formed with unpaired t test. The effects of dobutamine were
analyzed using a general linear modelling procedure. The
model allowed for analysis of the effects of dobutamine
within groups and also determined if there was significant
group by treatment interactions. A value of p  0.05 was
required for statistical significance.
RESULTS
Baseline characteristics. Baseline hemodynamic and neu-
rochemical characteristics are summarized in the Table 1.
The CHF group had reduced cardiac index and elevated
central filling pressures.
Hemodynamic responses. The final dobutamine infusion
rate was 2.7  0.2 g/kg per min in the normal LV
function group and 5.6  0.6 g/kg per min in the CHF
group (p  0.002, normal LV vs. CHF group). The LV
Abbreviations and Acronyms
CANESP  cardiac norepinephrine spillover
CHF  congestive heart failure
HPLC  high-performance liquid chromatography
LV  left ventricle/ventricular
dP/dt  rate of rise in left ventricular peak positive
pressure
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peak dP/dt increased by 38  8% in the normal LV
function group and by 42  5% in the CHF group (Table
2). The analysis revealed that there was no significant
interaction between the effect of dobutamine and patient
group (p  NS, normal vs. CHF). In the normal LV
function group, systemic arterial pressure parameters in-
creased in response to dobutamine, with the increase in
pulse pressure being the most prominent (74 3 mm Hg to
85  3 mm Hg, p  0.005). Dobutamine infusion caused
smaller increases in systemic arterial pressure parameters in
the CHF group, none of which were statistically significant.
There was no significant interaction between the systemic
arterial blood pressure effects of dobutamine and patient
group. Dobutamine did cause a significant decrease in LV
end-diastolic pressure during dobutamine infusion in the
CHF group (14  2 mm Hg to 11  2 mm Hg, p  0.02).
There was no significant change in LV end-diastolic pres-
sure in the normal LV function group; however, there was
a significant interaction between the effect of dobutamine
and patient group, indicating that the LV end-diastolic
pressure response in the CHF group was significantly
different from the response in the normal LV function
group. Hemodynamic measurements returned to baseline
after discontinuation of dobutamine.
Cardiac sympathetic responses. In the normal LV func-
tion group, dobutamine caused no change in CANESP
(0  11%, p  NS). In the CHF group, there was a large
and highly significant reduction in CANESP with dobut-
amine (36  8%, p  0.0009). There was a significant
group by treatment interaction indicating that the response
of CANESP in the CHF group was significantly different
from the response observed in the normal LV function
group (p  0.01; normal LV function vs. CHF group) (Fig
1). There was no difference between recontrol CANESP
measurements and baseline measurements.
Generalized sympathetic responses. Dobutamine had no
significant effect on total body norepinephrine spillover in
either group (Table 3). In both the normal LV function
group and the CHF group, dobutamine infusion was
associated with a significant increase in total body norepi-
nephrine clearance (Table 3).
Effects of beta-blocker treatment on responses to
dobutamine. Six patients in the CHF group were being
treated with beta-blockers. There was no difference in the
final dobutamine infusion dose between the patients on
Table 1. Baseline Hemodynamic and Neurochemical Data
Normal LV CHF
HR (beats/min) 60  4 77  4*
RA (mm Hg) 4  1 7  1*
PAmean (mm Hg) 13  1 24  3*
FAmean (mm Hg) 88  3 85  3
LV dP/dt (mm Hg/s) 1,217  103 855  61*
CI (l/min/m2) 3.3  0.3 2.4  0.2*
NEart (nmol/l) 0.7  0.1 1.9  0.3*
NEcs (nmol/l) 1.3  0.5 3.2  0.6*
TBNECL (l/min) 2.5  0.1 1.8  0.2*
TBNESP (nmol/min) 1.9  0.4 2.9  0.5
CANESP (pmol/min) 75  22 199  43*
*p 0.05. Data are presented as mean  SEM.
dP/dt  rate of rise in peak positive pressure; CANESP  cardiac norepineph-
rine spillover; CHF  congestive heart failure; CI  cardiac index; FAmean  mean
femoral artery pressure; HR heart rate; LV left ventricle; NEart arterial plasma
norepinephrine; NEcs  coronary sinus plasma norepinephrine; PAmean  mean
pulmonary artery pressure; RA  right atrial pressure; TBNECL  total body
norepinephrine clearance; TBNESP  total body norepinephrine spillover.
Table 2. Hemodynamic Responses to Dobutamine
Normal LV CHF
Control Dobutamine Control Dobutamine
HR (beats/min) 60  4 65  5 77  4 87  6*
RA (mm Hg) 4  1 4  1 7  1 7  1
PAmean (mm Hg) 13  1 14  1* 24  3 23  3
FAmean (mm Hg) 88  3 90  4 85  3 86  4
PP (mm Hg) 74  3 85  3* 58  6 65  5
LVEDP (mm Hg) 10  2 12  2 14  2 11  2*†
LV dP/dt (mm Hg/s) 1,217  103 1,686  170* 855  61 1,226  75*
CI (l/min per m) 3.3  0.3 3.7  0.3* 2.4  0.2 2.9  0.2*
*p 0.05 versus control; †p 0.05 response in CHF group versus response in normal LV group.
PP  pulse pressure. Data are presented as mean  SEM. Other abbreviations as in Table 1.
Figure 1. Cardiac norepinephrine spillover rate (CANESP) with dobut-
amine in the congestive heart failure (CHF) group versus the normal left
ventricular (LV) function group. Solid triangle  normal LV on no
beta-blocker; open triangle  normal LV on beta-blocker; open circle 
CHF on no beta-blocker; solid circle  CHF on beta-blocker. C 
control; Dob  Dobutamine. *p  0.05 vs. control; †p  0.05 response in
CHF group versus response in normal LV group.
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beta-blockers and those who were not (5.8  1.1 g/kg per
min vs. 5.3  0.6 g/kg/min, no beta-blocker vs. beta-
blocker, p  NS). Heart rate and cardiac output increased
significantly in both groups with dobutamine infusion with
no effect of beta-blockade on the magnitude of response.
Similarly, the CANESP responses to dobutamine were not
affected by beta-blocker treatment (39  12% vs. 33 
10%, no beta-blocker vs. beta-blocker, p  NS).
DISCUSSION
This investigation provides the first human in vivo descrip-
tion of the effects of dobutamine on CANESP rate, an
indirect index of cardiac sympathetic efferent neuronal
activity. Dobutamine was given intravenously and in clini-
cally relevant doses. We have demonstrated that dobut-
amine caused a significant reduction in CANESP, an
accepted index of efferent postganglionic nerve activity in
patients with CHF.
Sympathoexcitatory beta-adrenergic receptors. In this
investigation we hypothesized that dobutamine administra-
tion would cause an increase in cardiac sympathetic activity
through its effects, primarily, on beta1-adrenergic sympa-
thoexcitatory receptors located on intramural and juxtacar-
diac sympathetic ganglia and efferent postganglionic neu-
rons. These receptors have been described at a number of
levels within the intrathoracic sympathetic nervous system.
Classically, prejunctional beta2-adrenergic receptors are de-
scribed that facilitate neuronal norepinephrine release.
These receptors, and their functional significance, have been
described in a number of animals and humans (16,17). In a
previous report from our laboratory, we documented the
presence and functional importance of cardiac, sympatho-
excitatory beta2-adrenergic receptors in humans with nor-
mal ventricular function (18). In that study, we demon-
strated that salbutamol infusion increased CANESP by
124% and that the increase in norepinephrine release
mediated by beta2-adrenergic receptor stimulation made an
important contribution to the inotropic responses observed
(18). Recently, intracardiac, pericardiac and intrathoracic
sympathetic ganglia have been described that contain both
beta1- and beta2-adrenergic receptors that are involved in
the control of cardiac sympathetic responses (16,17,23).
These cardiac and intrathoracic sympathetic neurons have
been termed the “intrinsic cardiac sympathetic nervous
system” and are felt to play an important role in the
peripheral control of cardiac sympathetic responses (23).
Animal experiments have demonstrated that beta1-
adrenegic receptors in these neuronal systems can modulate
an increase in cardiac sympathetic activity (23).
Dobutamine effects in the normal LV group. In the
normal LV function group dobutamine had no significant
effect on CANESP. Despite this neutral response, we
cannot completely discount that a cardiac sympathoexcit-
atory effect occurred. Indeed, it is possible that a direct
sympathoexcitatory effect was offset by afferent reflexes that
were associated with a balanced withdrawal of central
sympathetic outflow. There would appear to be two poten-
tial mechanisms. First, dobutamine caused an increase in
systemic arterial pressure. Such stimulation of arterial
baroreceptors could have caused a reflex decrease in sympa-
thetic outflow. Second, the infusion of dobutamine may
have caused activation of ventricular mechanoreceptors.
Stimulation of these receptors has been shown to elicit reflex
decreases in sympathetic outflow, and the activity of these
receptors has been shown to increase in response to positive
inotropic therapy (24,25).
Dobutamine effects in the CHF group. Contrary to our
hypothesis, dobutamine caused a 36  8% reduction in
CANESP in the CHF group. This observation suggests
that sympathoinhibitory reflex responses are more relevant
than any direct sympathoexcitatory effects of dobutamine in
this patient population. Three possible reflex mechanisms to
account for sympathoinhibition can be suggested. As with
the normal LV function group, it is possible that arterial
baroreceptors played a role in the observed sympathoinhibi-
tory response. This seems unlikely because dobutamine had
essentially no effect on systemic arterial blood pressure,
while somewhat greater increases in systemic arterial pres-
sure in the normal LV function group had no effect on
CANESP. Second, it is also possible that the sympathoin-
hibitory effect of dobutamine in patients with CHF was
caused by a reduction in LV filling pressure. Dobutamine
caused a significant reduction in LV end-diastolic pressure
without reducing systemic arterial blood pressure. In a
previous report using lower body negative suction, we
demonstrated that a decrease in ventricular filling pressure
Table 3. Neurochemical Responses to Dobutamine
Normal LV CHF
Control Dobutamine Control Dobutamine
CSBF (ml/min) 107  10 141  22* 130  15 145  14*
NEart (nmol/l) 0.7  0.1 1.0  0.2 1.9  0.3 1.7  0.3
NEcs (nmol/l) 1.3  0.5 1.1  0.4 3.2  0.6 2.3  0.6*
TBNECL (l/min) 2.5  0.1 2.9  0.2* 1.8  0.2 1.9  0.2*
TBNESP (nmol/min) 1.9  0.4 1.7  0.4 2.9  0.5 2.7  0.6
CANESP (pmol/min) 75  22 72  22 199  43 128  30*†
*p  0.05 versus control; †p  0.05 response in CHF group versus response in normal LV group. Data are presented as
mean  SEM.
CSBF  coronary sinus blood flow. Other abbreviations as in Table 1.
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in the absence of a fall in systemic arterial blood pressure
was associated with a significant reduction in cardiac sym-
pathetic activity in patients with CHF (26). In the present
study, the reduction in LV filling pressure with dobutamine
was somewhat smaller than that seen with lower body
negative suction. Furthermore, right-sided filling pressures
did not change with dobutamine, while they did decrease
significantly with lower body negative suction. Therefore,
although it is possible that the reduction in LV filling
pressure made some contribution to the observed result, we
do not believe that the entire reduction in CANESP
occurred because of this small reduction in left-sided filling
pressure. Ventricular mechanoreceptor activation in re-
sponse to increased contractility provides a third potential
explanation for the observed decrease in cardiac sympathetic
activity (24,27,28). Activation of these receptors is associ-
ated with both attenuation in the sympathetic outflow to the
peripheral circulation and augmentation of vagal efferent
cardiac nerve activity (24). This increase in efferent cardiac
parasympathetic activity could explain the differential effects
of dobutamine on cardiac sympathetic norepinephrine spill-
over in the two groups. We have previously shown that
muscarinic receptor activation caused a reduction in
CANESP in patients with CHF, an effect not observed in
patients with normal LV function (29). In the CHF group
there was a significant increase in both heart rate and LV
dP/dt despite concurrent evidence of sympathetic with-
drawal. These differential responses are not inconsistent
because the former was the result of dobutamine’s postjunc-
tional beta-agonist activity.
There have been no previous investigations of the re-
sponse of the cardiac sympathetic nervous system to inotro-
pic agents like dobutamine. In a previous study, Colucci et
al. (30) demonstrated that systemic plasma norepinephrine
decreases in response to short-term infusions of dobutamine
in patients with CHF. These observations suggested that
dobutamine decreased systemic sympathetic activity in
CHF. Similarly, intracoronary and intravenous infusions of
milrinone in patients with CHF have been shown to reduce
systemic plasma norepinephrine concentrations (31). Im-
portantly, it is now recognized that the observed decrease in
plasma norepinephrine may have occurred secondary to
increases in norepinephrine clearance. Increases in cardiac
output are consistently observed in response to dobutamine
and milrinone in the setting of CHF, and we have previ-
ously demonstrated that increases in cardiac output correlate
closely with increases in norepinephrine clearance (32).
Study limitations. It is important to consider the limita-
tions of this study. We examined the acute effects of
intravenous dobutamine. The long-term effects of dobut-
amine infusion on cardiac sympathetic activity in patients
with CHF cannot be inferred from the present results. The
final infusion rate of dobutamine that was required to
achieve the same increase in LV dP/dt was almost twice
that required in the normal LV function group. This is not
surprising, given the well-documented beta1-receptor
downregulation in the myocardium of patients with CHF
(33). Direct measures of efferent sympathetic outflow to the
heart are not available in humans. We have hypothesized
that the reduction in CANESP that occurred in the CHF
group was mediated by a reduction in central sympathetic
outflow. Because cardiac efferent nerve activity cannot be
recorded in vivo, we cannot be definitive about this mech-
anism. For example, our measure of norepinephrine spill-
over is an indirect estimate of changes in norepinephrine
release, and we cannot rule out that some of the observed
reduction in CANESP was mediated by changes in norepi-
nephrine uptake mechanisms.
Conclusions. In summary, this investigation has demon-
strated that a short-term infusion of dobutamine caused a
significant reduction in efferent cardiac sympathetic activity
in patients with CHF. These observations are relevant given
the common clinical usage of dobutamine in this patient
population. The authors would like to emphasize that these
observations should not change present perceptions con-
cerning the safety of using inotropic agents in the treatment
of patients with CHF. At the moment, the utility of
dobutamine and other inotropic agents in the short-term
management of individual patients has an accepted place in
clinical practice. Their utility and safety when used routinely
in decompensated patients or intermittently as part of
long-term maintenance care remains controversial (14,34).
Our observation serves to establish that relatively selective
beta1-adrenergic agonists like dobutamine do not cause an
increase in cardiac sympathetic efferent neuronal activity
when used in patients with chronic heart failure.
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